Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS)-Reference-Cited by-同舟云学术

Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS)

Published:2022-11 Issue: Volume:176 Page:50-57
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bielack Stefan S.^ORCID,Blattmann Claudia,Borkhardt Arndt,Csóka Monika,Hassenpflug Wolf^ORCID,Kabíčková Edita,Kager Leo^ORCID,Kessler Thorsten^ORCID,Kratz Christian,Kühne Thomas^ORCID,Kevric Matthias,Lehrnbecher Thomas,Mayer-Steinacker Regine,Mettmann Vanessa,Metzler Markus^ORCID,Reichardt Peter,Rossig Claudia^ORCID,Sorg Benjamin,von Luettichau Irene,Windhager Reinhard^ORCID,Hecker-Nolting Stefanie

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference10 articles.

1. New horizons in the treatment of osteosarcoma;Meltzer;N Engl J Med,2021

2. Osteosarcoma – approach to therapy;Bielack,2021

3. Osteosarcoma: the COSS experience;Bielack;Cancer Treat Res,2009

4. A European study on chemotherapy in bone-sarcoma patients aged over 40: outcome in primary high-grade osteosarcoma;Ferrari;Tumori,2018

5. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort;Smeland;Eur J Cancer,2019

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cells;BMC Cancer;2024-02-12

2. Exploring the Impact of Exosomal Cargos on Osteosarcoma Progression: Insights into Therapeutic Potential;International Journal of Molecular Sciences;2024-01-01

3. Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cell;2023-12-12

4. Fusion Radiomics-Based Prediction of Response to Neoadjuvant Chemotherapy for Osteosarcoma;Academic Radiology;2023-12

5. An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives;Frontiers in Pharmacology;2023-10-04